Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: A five-year follow-up study

References

• Weetman, A. P. 2000. Graves’ disease. New. Eng. J. Med. 343: 1236–1248
   PubMed Web of Science ®Google Scholar
• Menconi, F., C. Marcocci, and M. Marino. 2014. Diagnosis and classification of Graves' disease. Autoimmune Rev. 13: 398–402
   PubMed Web of Science ®Google Scholar
• Burch, H. B., and L. Wartofsky. 1993. Graves’ ophthalmopathy: current concepts regarding pathogenesis and treatment. Endocr. Rev. 14: 747–793
   PubMed Web of Science ®Google Scholar
• Bahn, R. S. 2003. Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J. Clin. Endocrinol. Metab. 88: 1939–1946
   PubMed Web of Science ®Google Scholar
• Drexhage, H. A. 2006. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves’ disease? Endocrinology. 147: 9–12
   PubMed Web of Science ®Google Scholar
• Mengistu, M., Y. G. Lukes, E. V. Nagy, et al. 1994. TSH receptor gene expression in retroocular fibroblasts. J. Endocrinol. Invest. 17: 437–441
   PubMed Web of Science ®Google Scholar
• Weightman, D. R., P. Perros, I. H. Sherif, and P. Kendall-Taylor. 1993. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 16: 251–257
   PubMed Web of Science ®Google Scholar
• Bartalena, L., and M. L. Tanda. 2009. Clinical practice. Graves’ ophthalmopathy. New Engl. J. Med. 360: 994–1001
   PubMed Web of Science ®Google Scholar
• Pescivitz, M. D. 2006. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transpl. 6: 859–866
   PubMed Web of Science ®Google Scholar
• Nadler, L. M., J. Ritz, R. Hardy, et al. 1981. An unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67: 134–140
   PubMed Web of Science ®Google Scholar
• Reff, M. E., K. Carner, K. S. Chambers. 1994. Depletion of B cells in vivo by a chimerec mouse human monoclonal antibody to CD20. Blood. 83: 435–445
   PubMed Web of Science ®Google Scholar
• Maloney, D. G., B. Smith, and F. R. Apelbaum. 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines. Blood. 88: 637a
   Web of Science ®Google Scholar
• El Fassi, D., C. H. Nielsen, H. C. Hasselbalch, and L. Hegedüs. 2006. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol. 154: 623–632
   PubMed Web of Science ®Google Scholar
• El Fassi, D., O. Clemmensen, C. H. Nielsen, et al. 2007. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease. J. Clin. Endocrinol. Metab. 92: 3762–3763
   PubMed Web of Science ®Google Scholar
• Salvi, M., G. Vannucchi, I. Campi, et al. 2006. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol. 154: 511–517
   PubMed Web of Science ®Google Scholar
• Salvi, M., G. Vannucchi, I. Campi, et al. 2007. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open tudy. Eur. J. Endocrinol. 156: 33–40
   PubMed Web of Science ®Google Scholar
• El Fassi, D., C. H. Nielsen, H. C. Hasselbalch, and L. Hegedüs. 2006. Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 16: 709–710
   PubMed Web of Science ®Google Scholar
• Bonara, P., G. Vannucchi, I. Campi, et al. 2008. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for graves’ ophthalmopathy. Clin. Rev. Allergy Immunol. 34: 118–123
   PubMed Web of Science ®Google Scholar
• Salvi, M., G. Vannucchi, I. Campi, et al. 2009. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin. Immunol. 131: 360–365
   PubMed Web of Science ®Google Scholar
• Salvi, M., G. Vannucchi, I. Campi, et al. 2008. New immunomodulators in the treatment of Graves' ophthalmopathy. Ann. Endocrinol. (Paris). 69: 153–156
   PubMed Web of Science ®Google Scholar
• Datta, S. K. 2009. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat. Clin. Pract. Rheumatol. 5: 80–82
   PubMedGoogle Scholar
• Nielsen, J. F., D. El Fassi, and C. H. Nielsen, et al. 2009. Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy. Acta Ophthalmol. 87: 927–929
   PubMed Web of Science ®Google Scholar
• Mourits, M. P., M. F. Prummel, W. M. Wiersinga, and L. Koorneef. 1997. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. 47: 9–14
   PubMed Web of Science ®Google Scholar
• Galuska, L., A. Leovey, Z. Szucs-Farkas, et al. 2005. Imaging of disease activity in Graves' orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl. Med. Commun. 26: 407–414
   PubMed Web of Science ®Google Scholar
• Ujhelyi, B., A. Erdei, L. Galuska, et al. 2009. Retrobulbar 99mTc-diethylentriamine-pentaacetic-acid uptake may predict the effectiveness of immunosippressive therapy in Graves’ ophtalmopathy. Thyroid. 19: 375–380
   PubMedGoogle Scholar
• El Fassi, D., C. H. Nielsen, S. J. Bonnema, et al. 2007. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J. Clin. Endocrinol. Metab. 92: 1769–1772
   PubMed Web of Science ®Google Scholar
• Heemstra, K., R. Toes, J. Sepers, et al. 2008. Rituximab in relapsing Graves’ disease, a phase II study. Eur. J. Endocrinol. 159: 609–615
   PubMed Web of Science ®Google Scholar
• Chong, K. K., D. Khanna, N. F. Afifiyan, et al. 2010. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophtalmology. 117: 133–139
   PubMed Web of Science ®Google Scholar
• Vannucchi, G., I. Campi, M. Bonomi, et al. 2010. Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol. 161: 436–443
   PubMed Web of Science ®Google Scholar
• Mitchell, A. L., E. H. Gan, M. Morris, et al. 2013. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin. Endocrinol. 79: 437–442
   PubMed Web of Science ®Google Scholar
• Salvi, M., G. Vannucchi, N. Currò, et al. 2012. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action Arc. Ophthalmol. 130: 122–124
   Web of Science ®Google Scholar
• Savino, G., L. Balia, D. Colucci, et al. 2013. Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series. Minerva. Endocrinol. 38: 173–179
   Google Scholar
• El Fassi, D., C. H. Nielsen, P. Junker, et al. 2011. Systemic adverse events following rituximab therapy in patients with Graves’ disease. J. Endocrinol. Invest. 34: 163–167
   PubMed Web of Science ®Google Scholar
• Shawn, S., and A. R. Ahmed. 2013. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity. 46: 487–496
   PubMed Web of Science ®Google Scholar
• Kahaly, G., S. Plitz, W. Müller-Forell, and G. Hommel. 1996. Randomized trial of intravenous immunoglobulins versus prednisolon in Graves’ ophtalmopathy. Clin. Exp. Immunol. 106: 197–202
   PubMed Web of Science ®Google Scholar